CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,557 enrolled
Drug / intervention
Esomeprazole +2 moredrug
Likely dose
Esomeprazole 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00357682
NCT00357682Phase 3Completed
CompareCT.gov

A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia

University of Oxford·interventional·Posted Jul 27, 2006·Updated May 1, 2025

In Brief

A Phase 3 clinical trial evaluating Esomeprazole and Aspirin for Esophageal Cancer and Precancerous Condition. Completed, enrolled 2,557 participants.

Detailed Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of esomeprazole and aspirin may prevent esophageal cancer in patients with Barrett's metaplasia. It is not yet known whether esomeprazole is more effective with or without aspirin in preventing esophageal cancer in patients with Barrett's metaplasia. PURPOSE: This randomized phase III trial is studying esomeprazole with or without aspirin to compare how well they work in preventing esophageal cancer in patients with Barrett's metaplasia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer, Precancerous Condition
Countries--
CollaboratorsAstraZeneca

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 27, 2006
Enrollment StartMar 10, 2005
Primary CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 12.2 yearsPosted 19.9 years ago

Interventions

Esomeprazoledrug

20mg per day

Esomeprazoledrug

80mg per day

Aspirindrug

300mg per day